Peer-reviewed veterinary case report
Immune safety of new bioartificial liver treatment in dogs
By Zhang, Yue et al.·Published in The American journal of the medical sciences·2012·Department of Hepatobiliary Surgery, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunosafety evaluation of a multilayer flat-plate bioartificial liver.
- Species:
- dog
Plain-English summary
Ten beagles with acute liver failure were treated with a new bioartificial liver device to see if it was safe and effective. The dogs were given either one or three treatments with this device, and their health was closely monitored. Throughout the treatment, all the dogs remained stable, showing no significant immune reactions. The results suggest that this new treatment is safe for dogs with liver failure and could be a promising option for future clinical use.
People also search for: dog liver failure treatment · bioartificial liver for dogs · beagle liver disease therapy
Abstract
INTRODUCTION: To study and evaluate the immunosafety of our newly developed multilayer flat-plate bioartificial liver (BAL) in treatment of canines with acute liver failure. METHODS: Fresh porcine hepatocytes and bone marrow mesenchymal stem cells were cocultured in new BAL. Ten canine models with acute liver failure were set up through D-galactosamine administration; 24 hours after administration, the beagles were randomly allocated to a 6-hour treatment with the BAL. The beagles were divided into 2 groups by treatment times. Group 1 beagles (n = 5) received a single BAL treatment. Group 2 beagles (n = 5) received 3 BAL treatments. The hemodynamic, hematologic response and humoral immune responses to BAL therapy were studied before and after treatments. RESULTS: All beagles remained hemodynamically and hematologically stable during BAL treatments. The levels of IgG and IgM were similar before and after treatment after a single treatment. In addition, the level of CH50 in group 1 slightly decreased after the initiation of BAL treatment, and then the level recovered to baseline quickly after treatments. Time-course changes of the levels of antibodies and CH50 after 3 treatments in group 2 were similar to group 1. Only trace levels of IgG were detected in BAL medium after treatments. CONCLUSION: The multilayer flat-plate BAL showed a great immunosafety in the treatment of canines with acute liver failure and exhibited a good prospect of its use in clinic.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22008783/